Диссертация (1335885), страница 32
Текст из файла (страница 32)
Гендерныеособенноститерапиидепрессийуженщин.//Психиатрияипсихофармакотерапия.-2017.-5.-с.25-31.77.Ушкалова Е.А., Юргель Н.В., Хубиева М.Ю., Малин А.А.//Здравоохранение.-2010.-11.-с.15-27.78.ЧаховаК.О.,АведисоваА.С.Открытоесравнительноеисследование терапевтической эквивалентности адепресса и паксила(пароксетина) при терапии больных депрессивными расстройствами//Психиатрия и психофармакотерапия.-2009.-1.79.Чомский А.Н.
Опыт применения сердолекта в лечениирекуррентного депрессивного расстройства, резистентного к монотерапииантидепрессантами (клинический случай). Комментарии М.Ю.Дробижева //Психиатрия и психофармакттерапия.-2004.-6.-4.80.Шацберг А.Ф., Коул Дж.О., Де Баттиста Ч. Руководство поклинической фармакологии / Пер. с англ.; под ред. А.Б.Смулевича,С.В.Иванова. М.: МЕДпресс-информ, 2014: 21581.Шмуклер А.Б. Применение амисульприда в клиническойпрактике.//Социальная и клиническая психиатрия.-2004.- 14.- 4.- с. 87-90.82.Щербаков В.
ВОЗ вмешивается в производство дженериков//Редмедиум.-2000.-№4.,с.62-65.83.«FDA внесло изменения в инструкцию по применениюклозапина.»// Фарматека. – 2009. - №7. – с.6.84.Якусевич В.В. Качественное лекарственное средство: каким онодолжно быть?//Рациональная фармакотерапия в кардиологии.-2006.-4.-с.4146.17085.Ястребов Д.В. Терапевтически резистентные депрессии вклинике пограничной психиатрии.//Ж. неврологии и психитрии.–2011.-№4.–с.47–50.86.Abbas A.I., Hedlund P.B., huang X.P., Tran T.B., Meltzer H.Y.,Roth B.L.
Amisulprid is a potent 5-HT 7 antagonist: relevance for antidepressantactions in vivo.// Psychopharmacology (Berl.). – 2009. – 205(1). – p. 119 – 128.87.Adson D.E., KushnerM.G., Eiben K.M., Schulz S.C. Preliminaryexperience with adjunctive quetiapine in patients receiving selective serotoninreuptake inhibitors.//Depression and Anxiety.-2004.-19.-p.121-126.88.Aldurra G., Crayton J.W. Improvement of hallucinogen persistingperception disorder by Treatment with a combination of fluoxetine andolanzapine: case report.//J. Clin. Psychopharmacol.-2001.- Jun. 21 (3).-p.343-34489.Alfaro C.L., Nicolson R., Lenane M., Rapoport J.L.
Carbomazepineand/or fluvoxamine drug interaction with risperidone in a patient on multiplepsychotropic medications (letter).//Ann Pharmacother.-2000.- Jan. 34 (1).-p.122123.90.Amore M., Jori M.C. Faster response on amisulpride 50 mg. versussertraline 50-100 mg. in patients with dystymia or double depression : arandomized, double – blind, parallel group study // Jnt. Clin. Psychopharmacol. –2001. – Nov.
16 (6). – p. 317 – 324.91.Anderson L.M., Nutt D.J., Deakin J.E.W. Evidence – basedguidelines for treating depressive illnessantidepressant:arevisionofthewith antidepressive illness with1993BritishAssociationforPsychopharmacology guidelines.// J. Psychopharmacol. – 2000. – 14. – p. 3 – 20.92.Angst J., Preying M. Outcome of a clinical cohort of unipolar,bipolar and schizoaffective patients.
Resalts of a prospective study from 1959 to1985. //Schweiz. Arch. Neurol. Psychiatr. – 1995. – 146. – 1. – p. 17 – 23.93.fluoxetineAvenoso A., Spina E., Campoandhaloperidole:T. et al. Interaction betweenpharmacokineticimplications.//Pharmacol. Res.-1997.-35.-4.-p.335-339.andclinical17194.Baldwin D, Rudge S, Thomas S (1995) Dysthymia.// Options inpharmacotherapy.// CNS Drugs. – 4.-p. 422-43195.Barbee J.G., Conrad E.J., Jamhour N.J. The effectiveness ofolansapine, risperidone, quetiapine, and ziprasidone as augmentation agents intreatment-resistant major depressive disorder.//Journal of Clinical Psychiatry –2004.- 65.(7). - p. 975 – 981.96.Bauer M., Severus E., Kohler S., Whybrow P., Angst J., Mueller H.Word Federation of Societies of Biological Psychiatry (WFSBP) Guidelines forbiological treatment of unipolar depressive disorder Update 2015//World J.
Biol.Psychiatr.-2015.-16.-p.76-9597.Baune B.T. New developments in the management of majordepressivedisorderandgeneralizedanxietydisorder:roleofquetiapine.//Neuropsychiatr. Dis. Treat.-2008.-4(6).-p.1181-1191.98.Baune B.T., Eyre H. Anti-inflammatory effects of antidepressant andatypical antipsychotic medication for the nreatment of major depression andcomorbid arthritis a case report // J.Med. Case Reports.-2010.-12.-p.4-6.99.Bazir S. Psychotropic drug directory.//Fivepin Limited. - Wilts. -2005 - 392 p.100.Benazzi F., Berk M., Frye M.A., Wang W., Barraco A., Tohen M.Olanzapine/fluoxetine combination for the treatment of mixed depression inbipolar 1 disorder: a post hoc analysis.// J. Clin. Psychiatry. – 2009.
– 70(10). – p.1424 – 1431.101.Berman R.M., Fava M., Thase M.E., Trivedi M.H., Swanink R., McQude R.D., Carson w.h., Adson D., Taylor L., Hazel J., Marcus R.N.Aripiprazole augmentation in major depressive disorder: a double – blind,placebo – controlled study in patients with inadequate response toantidepressants.// CNS Spectr. – 2009. – 14(4). – p. 197-206.102.Bingnooghe F., Geerts S., Van Maele G., Vogtle Jungert U.Behaudlung reactiver depressionen mit sulprid.
Doppel – blindstudie mit sulpridund amitriptylin iminterindividuellen Vergleich // Fortschr. Med. – 1992. – 110 p.172103.Blier P., Szabo S.T. Potential mechanisms of action of atypicalantipsychotic medications in treatment-resistant depression and anxiety.//J.Clin.Psychiatry.- 2005.- 66.- 8.- p.30-40.104.Bobo W.V., Shelton R.C. (1) Fluoxetine and olanzapine combinationtherapy in treatment – resistant major depression: review of efficacy and safetydata.// Expert Opin Pharmacother. – 2009. – 10(3). – p.
2145 – 2159.105.Bobo W.V., Shelton R.C. (2)Olanzapine and fluoxetinecombination therapy for treatment – resistant depression: review of efficacy,safety, and study design issues.// Neuropsychiatr. Dis. Treat. – 2009. – 5(3). – p.369-383.106.Bocchetta A., Bernardi F., Burrani C. et al. A double – blind studyof L – sulpride versus amitriptyline in lithium – maintained bipolar depressive.//Acta Psychiatrica Scand. – 1993. – 88.
– p. 434 – 439.107.Bogetto F., Barsega G., Bellino S. et al. Drag treatment of dystimia:A clinical study.// Rivista di Psichiatria. – 1997. - №1. – p. 1 – 5.108.Borgherini G. The bioeguiovalence andtherapeutic efficacy ofgeneric versus brand-name psychoactive drugs.//Clin.Ther.
- 2003. -25. -p.15781592.109.Boyer P., Lecrubier Y., Stalla – Bourdillon A.,Fleurot O..Amisulpride versus amineptine and placebo for the treatment of dysthymia.//Neuropsychobiology. – 1999. – 39 (1). – p. 25-32110.Boyer P., Lecrubier V., Puech A.J.et al. Treatment of dystymia withlow – dose amisulprid versus amineptine.//Clin.
Neurofarmacol. – 1992. – 15. –supp. 1. – p. 524 – 528.111.Bozikas V., Petrikis P., Karavatos A. Urinary retention caused afterfluoxetine – risperidone combination.//J. Psychopharmacol. - 2001. - Jun. 15 (2).– p. 142-143.112.Bellino S., Paradiso E., Bogetto F. Eficacy and tolerability ofaripiprazole augmentation in sertraline – resistant patients with borderlinepersonality disorder. // Psychiatry Res.
– 2008. – Nov. 30. – 161(2). – p. 206-212.173113.BenazziF.Gynecomastiawithrisperidone–fluoxetinecombination.//Pharmacopsychiatry. - 1999. - Jan. 32 (1). – p.41.114.Briley M. Milnacipram, a well tolerated specific serotonin andnorepinephrine reuptake inhibiting antidepressant.//CNS Drug Reviews. – 1998. –4. – 2. – p. 177 – 148.115.Bschor T., Ising M. , Erbe S. et al. Impact of citalopram on the HPAsystem. A study of the combined DEX/CRH test in 30 unipolar depressedpatients//J.Psychiatr.res.-2012.-46.-1,-p.111-117.116.Capurou L., Raison C.L., Musselman D.L., Lawson D.H., NemeroffC.B., Miller A.H. Association of exaggerated HPA axis response to the initialinjection of interferon-alpha with development of depression during interferonalpha therapy.//Am.J.Psychiatry.-2003.-160.-7.-p.1342-1345.117.Cassano G.B., Jori M.C. Efficacy and safety of amisulpride 50 mg.versus paroxetine 20 mg.
in major depression: a randomized, double – blind,parallel group study. // Jnt. Clin. Psychopharmacol. – 2002. – 17. – 1. - p. 27 –32.118.Cattapan – Zudewig K., Seifritz E. Antipsychotics.// Ther. Umsch. –2009. – 66(6). – p. 402-406.119.Chaichan W. Olanzapine plus fluvoxamine and olanzapine alon forthe treatment of an acute exacerebration of schisoprenia.//Psychiatry. Clin.Neurosci.
-2004.-58.-4.-p.364-368.120.Chaudhury D., Liu H., Han M.Н. Neuronal correlates ofdepression.//Cell Mol Life Sci.- 2015.- 72 (24).- р.25-48.121.Chen J.J., Lin Z., Zhu D.,Li Q., Huang H., Wei Y., Mu J., Yang D.,Xie P. Bilateral vs. unilateral repetitive transcranial magnetic stimulation intreating major depression: a meta-analysis of randomized controlled trials.//Psychiatry resorch.-2014.-219.-1.-p.51-57.122.Chopra P., Chee N., Schweitzer J. Serotonin syndrome accociatedwith fluoxetine and olanzapine // Wed. J. Biol.
Psychiat. – 2004. – 5 (2). – p.114– 115.174123.Cipriani A., Rendell J.M., Geddes J. Olanzapine in long – termtreatment for bipolar disorder.// Cochrane Data – base syst.Rev. – 2009. – 21(1).– CD004367.124.Constantine R.J., Boaz T., Tandon R. Antipsychotic polypharmacy inthe treatment of children and adolescents in the fee for service component of alarge state Medical program.//Clin.
Ther.-2010.-32.-5.-p.949-959.- doi: 10.1016/J. Clinthera. 2010.04.021.125.Corya S.A., Williamson D., Sauger T.M. et al. A randomized, doubl-blind comparison of olanzapine/fluoxetine, and renlafaxine in treatment resistant depression.// Depression and auxiety, - 2006. – 23. – p. 364 – 372.126.Costa - Silva E. Treitment des dysthymies par des faibles doses d'amisulpride. Etud comparative amisulpride 50 mg/j versus placebo.//Ann.Psychiat.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
